Blog
RSS FeedPosted by Michael Wonder on 04 May 2021
Uncertain effect and high prices of precision medicine are challenging
3 May 2021 - In a report to the government, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, describes the most ...
Posted by Michael Wonder on 04 May 2021
Andrew Little not pleased with Children's Commissioner comments on potential PHARMAC move
4 May 2021 - Heath Minister Andrew Little says he expects better of the Children's Commissioner after he described a potential ...
Posted by Michael Wonder on 29 Apr 2021
Integration of ethical considerations into HTA reports: an analysis of integration levels using a systematic review
26 April 2021 - The objective was to describe the type and level of ethical integration in published health technology assessment ...
Posted by Michael Wonder on 28 Apr 2021
Do existing real world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal
28 April 2021 - Technological and computational advancements offer new tools for the collection and analysis of real world data. ...
Posted by Michael Wonder on 28 Apr 2021
NICE signs up to join the GetReal Institute
28 April 2021 -NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence ...
Posted by Michael Wonder on 15 Apr 2021
Medicare Benefits Schedule Electrocardiogram Review Committee – appointment of Committee Members
15 April 2021 - The Medicare Benefits Schedule Review Committee was established in March 2021 to review electrocardiogram items introduced on ...
Posted by Michael Wonder on 12 Apr 2021
Prevalence of immature survival data for anti-cancer drugs presented to the National Institute for Health and Care Excellence and impact on decision-making
12 April 2021 - This research aims to explore how often NICE uses immature overall survival data to inform reimbursement ...
Posted by Michael Wonder on 06 Apr 2021
Decision to widen access to secukinumab for psoriatic arthritis and ankylosing spondylitis
1 April 2021 - PHARMAC is pleased to announce a decision to widen funded access to secukinumab (Cosentyx) for the ...
Posted by Michael Wonder on 06 Apr 2021
Development of an international template to support patient submissions in health technology assessments
1 April 2021 - The objective was to develop an international template to support patient submissions in health technology assessments. ...
Posted by Michael Wonder on 17 Mar 2021
Mythbusting PHARMAC
17 March 2021 - The agency is seeking to dispel some misunderstandings about what it does and how it does ...
Posted by Michael Wonder on 17 Mar 2021
PHARMAC’s drug switch
17 March 2021 - PHARMAC's generic drug swap for epilepsy treatment saved $30 million over five years. But for some ...
Posted by Michael Wonder on 08 Mar 2021
Pacific pharmacists want inclusion on PHARMAC review
6 March 2021 - The President of the Pacific Pharmacists’Association, Kasey Brown, says a review of New Zealand’s drug buying ...
Posted by Michael Wonder on 08 Mar 2021
Is the Department of Health guilty of abusing its monopsonistic power?
8 March 2021 - In these times of heightened sensitivities, is it time the folks in Canberra got called out ...
Posted by Michael Wonder on 08 Mar 2021
More startling revelations from the Public Summary Document for upadacitinib monohydrate (Rinvoq)
8 March 2021 - Take a seat before reading any further. ...
Posted by Michael Wonder on 08 Mar 2021
Jacinda Ardern responds to heartfelt plea from PHARMAC funding advocate Malcolm Mulholland
8 March 2021 - Prime Minister Jacinda Ardern has responded to a heartfelt plea by Malcolm Mulholland, a man advocating ...